These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37991922)

  • 81. Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases.
    Mamais A; Raja M; Manzoni C; Dihanich S; Lees A; Moore D; Lewis PA; Bandopadhyay R
    Neurobiol Dis; 2013 Oct; 58():183-90. PubMed ID: 23747310
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Monoamine Oxidase-B Inhibition Facilitates α-Synuclein Secretion
    Nakamura Y; Arawaka S; Sato H; Sasaki A; Shigekiyo T; Takahata K; Tsunekawa H; Kato T
    J Neurosci; 2021 Sep; 41(35):7479-7491. PubMed ID: 34290084
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Modeling Parkinson's disease in adult Drosophila.
    Dabool L; Juravlev L; Hakim-Mishnaevski K; Kurant E
    J Neurosci Methods; 2019 Jan; 311():89-94. PubMed ID: 30336223
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Bent out of shape: α-Synuclein misfolding and the convergence of pathogenic pathways in Parkinson's disease.
    Luna E; Luk KC
    FEBS Lett; 2015 Dec; 589(24 Pt A):3749-59. PubMed ID: 26505673
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Induction of the Immunoproteasome Subunit Lmp7 Links Proteostasis and Immunity in α-Synuclein Aggregation Disorders.
    Ugras S; Daniels MJ; Fazelinia H; Gould NS; Yocum AK; Luk KC; Luna E; Ding H; McKennan C; Seeholzer S; Martinez D; Evans P; Brown D; Duda JE; Ischiropoulos H
    EBioMedicine; 2018 May; 31():307-319. PubMed ID: 29759483
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Selective detection, quantification, and subcellular location of alpha-synuclein aggregates with a protein aggregate filtration assay.
    Kramer ML; Behrens C; Schulz-Schaeffer WJ
    Biotechniques; 2008 Mar; 44(3):403-11. PubMed ID: 18361794
    [TBL] [Abstract][Full Text] [Related]  

  • 87. The behavior of alpha-synuclein in neurons.
    Fortin DL; Nemani VM; Nakamura K; Edwards RH
    Mov Disord; 2010; 25 Suppl 1():S21-6. PubMed ID: 20187244
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Therapeutic approaches to target alpha-synuclein pathology.
    Brundin P; Dave KD; Kordower JH
    Exp Neurol; 2017 Dec; 298(Pt B):225-235. PubMed ID: 28987463
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Parkinson's Disease-Associated LRRK2 Interferes with Astrocyte-Mediated Alpha-Synuclein Clearance.
    Streubel-Gallasch L; Giusti V; Sandre M; Tessari I; Plotegher N; Giusto E; Masato A; Iovino L; Battisti I; Arrigoni G; Shimshek D; Greggio E; Tremblay ME; Bubacco L; Erlandsson A; Civiero L
    Mol Neurobiol; 2021 Jul; 58(7):3119-3140. PubMed ID: 33629273
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Protocol to investigate Parkinson's patient-derived dopaminergic neurons by live-cell microscopy and oxidized dopamine assays.
    Song P; Krainc D
    STAR Protoc; 2024 Mar; 5(1):102889. PubMed ID: 38341851
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Protocol for screening α-synuclein PET tracer candidates in vitro and ex vivo.
    Xiang J; Xia Y; Luo S; Zhang Z; Ye K
    STAR Protoc; 2024 Mar; 5(1):102788. PubMed ID: 38117656
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Optogenetic and chemogenetic manipulation of seizure threshold in mice.
    Kravchenko JA; Goldberg EM; Mattis J
    STAR Protoc; 2023 Mar; 4(1):102019. PubMed ID: 36640370
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Simultaneous analysis of social behaviors and neural responses in mice using round social arena system.
    Kim S; Kim YE; Kim IH
    STAR Protoc; 2022 Dec; 3(4):101722. PubMed ID: 36153733
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Protocol to investigate the neural basis for copulation posture of Drosophila using a closed-loop real-time optogenetic system.
    Yamanouchi HM; Kamikouchi A; Tanaka R
    STAR Protoc; 2023 Dec; 4(4):102623. PubMed ID: 37788165
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Protocol to visualize ion channel trafficking in acutely isolated rodent neurons using live-cell immunocytochemistry.
    Haan KD; Fisher TE
    STAR Protoc; 2023 Dec; 4(4):102744. PubMed ID: 37999972
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Protocol to induce neurodegeneration in a local area of the mouse brain by stereotaxic injection.
    Zhang X; Lu Q; Meng X; Kim JY
    STAR Protoc; 2024 Sep; 5(3):103243. PubMed ID: 39096497
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Optogenetic-mediated induction and monitoring of α-synuclein aggregation in cellular models of Parkinson's disease.
    Teixeira M; Sheta R; Idi W; Oueslati A
    STAR Protoc; 2023 Dec; 4(4):102738. PubMed ID: 37991922
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Optogenetic induction of alpha-synuclein aggregation in human dopaminergic neurons to model Parkinson's disease pathology.
    Ra EA; Kim MS; Lee G
    STAR Protoc; 2023 Dec; 4(4):102609. PubMed ID: 37742181
    [TBL] [Abstract][Full Text] [Related]  

  • 99. A53T-α-synuclein overexpression in murine locus coeruleus induces Parkinson's disease-like pathology in neurons and glia.
    Henrich MT; Geibl FF; Lee B; Chiu WH; Koprich JB; Brotchie JM; Timmermann L; Decher N; Matschke LA; Oertel WH
    Acta Neuropathol Commun; 2018 May; 6(1):39. PubMed ID: 29747690
    [TBL] [Abstract][Full Text] [Related]  

  • 100. rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration.
    Oliveras-Salvá M; Van der Perren A; Casadei N; Stroobants S; Nuber S; D'Hooge R; Van den Haute C; Baekelandt V
    Mol Neurodegener; 2013 Nov; 8():44. PubMed ID: 24267638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.